GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (STU:PCBK) » Definitions » EV-to-EBIT

Sesen Bio (STU:PCBK) EV-to-EBIT : 1.43 (As of May. 24, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Sesen Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sesen Bio's Enterprise Value is €-48.38 Mil. Sesen Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was €-33.92 Mil. Therefore, Sesen Bio's EV-to-EBIT for today is 1.43.

The historical rank and industry rank for Sesen Bio's EV-to-EBIT or its related term are showing as below:

STU:PCBK's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 10.43
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sesen Bio's Enterprise Value for the quarter that ended in Dec. 2022 was €-34.64 Mil. Sesen Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was €-33.92 Mil. Sesen Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was 97.92%.


Sesen Bio EV-to-EBIT Historical Data

The historical data trend for Sesen Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio EV-to-EBIT Chart

Sesen Bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.32 -1.71 -4.25 0.01 1.13

Sesen Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.42 -0.29 3.52 1.13

Competitive Comparison of Sesen Bio's EV-to-EBIT

For the Biotechnology subindustry, Sesen Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sesen Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sesen Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sesen Bio's EV-to-EBIT falls into.



Sesen Bio EV-to-EBIT Calculation

Sesen Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-48.380/-33.918
=1.43

Sesen Bio's current Enterprise Value is €-48.38 Mil.
Sesen Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-33.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sesen Bio  (STU:PCBK) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sesen Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2022 ) =EBIT / Enterprise Value (Q: Dec. 2022 )
=-33.918/-34.6398246
=97.92 %

Sesen Bio's Enterprise Value for the quarter that ended in Dec. 2022 was €-34.64 Mil.
Sesen Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-33.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sesen Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sesen Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sesen Bio (STU:PCBK) Business Description

Traded in Other Exchanges
N/A
Address
245 First Street, Suite 1800, Cambridge, MA, USA, 02142
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Sesen Bio (STU:PCBK) Headlines

From GuruFocus

Pacific Continental Corp. (PCBK) President/COO Roger S Busse buys 1,000 Shares

By GuruFocus Research GuruFocus Editor 10-15-2009

Pacific Continental Corp. (PCBK) CEO Hal Brown buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 10-15-2009

Pacific Continental Corp. (PCBK) CFO Michael Reynolds sells 1,650 Shares

By GuruFocus Research GuruFocus Editor 02-22-2010